First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid

YUNG-TSU CHOCHIA-YU CHUWang L.F.2019-12-042019-12-042015-070007-0963https://www.scopus.com/inward/record.uri?eid=2-s2.0-84948719751&doi=10.1111%2fbjd.13633&partnerID=40&md5=6b547f7fc8c5ab67cc9fe5ab8e607439https://scholars.lib.ntu.edu.tw/handle/123456789/434902en[SDGs]SDG3autoantibody; prednisolone; rituximab; corticosteroid; dermatological agent; rituximab; adult; aged; bullous pemphigoid; case control study; clinical article; comorbidity; controlled study; disease severity; eosinophil count; female; follow up; human; immunofluorescence; infection risk; Letter; male; patient referral; pneumonia; priority journal; remission; retrospective study; systemic therapy; treatment duration; urinary tract infection; drug combination; middle aged; Pemphigoid, Bullous; remission; treatment outcome; very elderly; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Case-Control Studies; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pemphigoid, Bullous; Remission Induction; Retrospective Studies; Rituximab; Treatment OutcomeFirst-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoidletter10.1111/bjd.13633255293942-s2.0-84948719751